tradingkey.logo


tradingkey.logo


HUTCHMED (China) Ltd

HCM
13.810USD
-0.350-2.47%
終倀 03/27, 16:00ET15分遅れの株䟡
2.41B時䟡総額
25.54盎近12ヶ月PER


HUTCHMED (China) Ltd

13.810
-0.350-2.47%

詳现情報 HUTCHMED (China) Ltd 䌁業名

HUTCHMED (China) Ltd is an investment holding company principally engaged in the manufacture and sale of pharmaceuticals. The Company operates its business through two segments. Oncology Immunology segment is engaged in the discovery, development and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. Among it, research and development (R&D) includes research and development activities covering drug discovery, development, manufacturing and regulatory functions, out-licensing of in-house developed drugs, as well as administrative activities to support research and development operations, marketed products comprises the invoiced sales, marketing, manufacture and distribution of drugs developed from research and development activities. Other Ventures segment is engaged in the other commercial businesses which include the sales, marketing, manufacture and distribution of other prescription drugs and healthcare products.

HUTCHMED (China) Ltdの䌁業情報


䌁業コヌドHCM
䌚瀟名HUTCHMED (China) Ltd
䞊堎日May 19, 2006
最高経営責任者「CEO」Cheng (Chig Fung)
埓業員数1811
蚌刞皮類Depository Receipt
決算期末May 19
本瀟所圚地48th Floor, Cheung Kong Center, 2 Queen's Road Central
郜垂
蚌刞取匕所NASDAQ OMX - NASDAQ BASIC
囜Hong Kong
郵䟿番号- -
電話番号85221281188
りェブサむトhttps://www.hutch-med.com/
䌁業コヌドHCM
䞊堎日May 19, 2006
最高経営責任者「CEO」Cheng (Chig Fung)

HUTCHMED (China) Ltdの経営陣


䌚瀟名
䌚瀟名/ポゞション
ポゞション
株匏保有
倉動額
Dr. Renu Bhatia
Dr. Renu Bhatia
Independent Non-Executive Director
Independent Non-Executive Director
16.00K
--
Ms. Edith Shih
Ms. Edith Shih
Non-Executive Director, Company Secretary
Non-Executive Director, Company Secretary
--
--
Mr. Chig Fung (Johnny) Cheng
Mr. Chig Fung (Johnny) Cheng
Acting Chief Executive Officer, Chief Financial Officer, Executive Director
Acting Chief Executive Officer, Chief Financial Officer, Executive Director
--
--
Dr. Dan Eldar, Ph.D.
Dr. Dan Eldar, Ph.D.
Non-Executive Chairman of the Board
Non-Executive Chairman of the Board
--
--
Dr. Weiguo Su, Ph.D.
Dr. Weiguo Su, Ph.D.
Chief Scientific Officer, Executive Director
Chief Scientific Officer, Executive Director
--
--
Prof. Shu Kam (Tony) Mok
Prof. Shu Kam (Tony) Mok
Senior Lead Non-Executive Independent Director
Senior Lead Non-Executive Independent Director
--
--
Dr. Qingmei (May) Wang, Ph.D.
Dr. Qingmei (May) Wang, Ph.D.
Senior Vice President - Business Development and Strategic Alliances
Senior Vice President - Business Development and Strategic Alliances
--
--
Dr. Zhenping Wu, Ph.D.
Dr. Zhenping Wu, Ph.D.
Executive Vice President - Pharmaceutical Sciences and Manufacturing
Executive Vice President - Pharmaceutical Sciences and Manufacturing
--
--
Mr. Kin Hung (Mark) Lee
Mr. Kin Hung (Mark) Lee
Senior Vice President - Corporate Management and Communications
Senior Vice President - Corporate Management and Communications
--
--
Mr. Charles George Rupert Nixon
Mr. Charles George Rupert Nixon
Group General Counsel
Group General Counsel
--
--
詳现を芋る
䌚瀟名
䌚瀟名/ポゞション
ポゞション
株匏保有
倉動額
Dr. Renu Bhatia
Dr. Renu Bhatia
Independent Non-Executive Director
Independent Non-Executive Director
16.00K
--
Ms. Edith Shih
Ms. Edith Shih
Non-Executive Director, Company Secretary
Non-Executive Director, Company Secretary
--
--
Mr. Chig Fung (Johnny) Cheng
Mr. Chig Fung (Johnny) Cheng
Acting Chief Executive Officer, Chief Financial Officer, Executive Director
Acting Chief Executive Officer, Chief Financial Officer, Executive Director
--
--
Dr. Dan Eldar, Ph.D.
Dr. Dan Eldar, Ph.D.
Non-Executive Chairman of the Board
Non-Executive Chairman of the Board
--
--
Dr. Weiguo Su, Ph.D.
Dr. Weiguo Su, Ph.D.
Chief Scientific Officer, Executive Director
Chief Scientific Officer, Executive Director
--
--
Prof. Shu Kam (Tony) Mok
Prof. Shu Kam (Tony) Mok
Senior Lead Non-Executive Independent Director
Senior Lead Non-Executive Independent Director
--
--

収益内蚳

通貚: USD曎新時刻: Tue, Jan 6
通貚: USD曎新時刻: Tue, Jan 6
FY2024
FY2023
FY2022
FY2021
FY2020
䌚瀟から関連デヌタがただ開瀺されおいたせん。
地域別USD
䌚瀟名
収益
比率
PRC
630.20M
0.00%
Unallocated
0.00
0.00%
事業別
地域別
䌚瀟から関連デヌタがただ開瀺されおいたせん。

株䞻

曎新時刻: Sun, Mar 22
曎新時刻: Sun, Mar 22
株䞻統蚈
皮類
株䞻統蚈
株䞻統蚈
比率
Schroder Investment Management (Singapore) Ltd.
0.93%
Allianz Global Investors Asia Pacific Limited
0.49%
Schroder Investment Management (Hong Kong) Ltd.
0.37%
State Street Investment Management (US)
0.18%
AIA Group Ltd
0.18%
他の
97.83%
株䞻統蚈
株䞻統蚈
比率
Schroder Investment Management (Singapore) Ltd.
0.93%
Allianz Global Investors Asia Pacific Limited
0.49%
Schroder Investment Management (Hong Kong) Ltd.
0.37%
State Street Investment Management (US)
0.18%
AIA Group Ltd
0.18%
他の
97.83%
皮類
株䞻統蚈
比率
Investment Advisor/Hedge Fund
2.22%
Investment Advisor
0.61%
Hedge Fund
0.11%
Research Firm
0.09%
Bank and Trust
0.03%
他の
96.93%

機関投資家保有株


曎新時刻: Thu, Jan 1
曎新時刻: Thu, Jan 1
報告期間
機関投資家数
保有株匏数
比率
倉動額
2025Q4
143
5.83M
3.34%
-5.83M
2025Q3
144
6.22M
3.56%
-5.80M
2025Q2
160
6.97M
3.99%
-6.31M
2025Q1
166
6.98M
4.00%
-6.73M
2024Q4
187
7.28M
4.18%
-8.01M
2024Q3
259
7.73M
4.44%
-16.35M
2024Q2
280
9.29M
5.33%
-17.79M
2024Q1
306
15.01M
8.61%
-19.39M
2023Q4
327
16.63M
9.55%
-27.28M
2023Q3
339
25.00M
14.36%
-20.50M
詳现を芋る

株䞻動向


䌚瀟名
保有株匏数
比率
倉動額
倉動率
日付
Schroder Investment Management (Singapore) Ltd.
1.69M
0.97%
-84.85K
-4.78%
Sep 30, 2025
Allianz Global Investors Asia Pacific Limited
863.00K
0.49%
-15.73K
-1.79%
Sep 30, 2025
Schroder Investment Management (Hong Kong) Ltd.
778.26K
0.45%
-27.37K
-3.40%
Sep 30, 2025
State Street Investment Management (US)
317.50K
0.18%
-11.29K
-3.43%
Sep 30, 2025
AIA Group Ltd
315.44K
0.18%
--
--
Sep 30, 2025
M&G Investment Management Ltd.
204.43K
0.12%
-55.19K
-21.26%
Sep 30, 2025
Amundi Asset Management, SAS
223.33K
0.13%
+65.90K
+41.86%
Sep 30, 2025
Renaissance Technologies LLC
131.00K
0.08%
+2.00K
+1.55%
Sep 30, 2025
Jane Street Capital, L.L.C.
340.34K
0.2%
+164.38K
+93.42%
Sep 30, 2025
Saint Olive Gestion
100.00K
0.06%
--
--
Sep 30, 2025
詳现を芋る

関連ETF


曎新時刻: Sat, Dec 6
曎新時刻: Sat, Dec 6
銘柄名
比率
Tema Oncology ETF
0.78%
National Security Emerging Markets Index ETF
0.35%
Invesco Nasdaq Biotechnology ETF
0.05%
ProShares Ultra Nasdaq Biotechnology
0.05%
DFA Dimensional Emerging Markets Core Equity 2 ETF
0%
DFA Dimensional Em Mkts Sustainability Core 1 ETF
0%
ActivePassive International Equity ETF
0%
SPDR Portfolio Developed World ex-US ETF
0%
Tema Oncology ETF
比率0.78%
National Security Emerging Markets Index ETF
比率0.35%
Invesco Nasdaq Biotechnology ETF
比率0.05%
ProShares Ultra Nasdaq Biotechnology
比率0.05%
DFA Dimensional Emerging Markets Core Equity 2 ETF
比率0%
DFA Dimensional Em Mkts Sustainability Core 1 ETF
比率0%
ActivePassive International Equity ETF
比率0%
SPDR Portfolio Developed World ex-US ETF
比率0%

配圓金


過去5幎間の配圓金総支払額は 0.00 米ドルである。
日付
配圓金
暩利確定日
支払日
配圓萜ち日
デヌタなし

株匏分割


日付
配圓萜ち日
皮類
比率
デヌタなし
日付
配圓萜ち日
皮類
比率
デヌタなし
KeyAI
î™